Treatment of viral hepatitis in recipients of renal allograft (Review)
Abstract
The review provides the current concept on the efficacy and safety of various schemes of antiviral therapy for viral hepatitis in renal transplant recipients. It also provides a brief overview of the method of double-filtration plasmapheresis the treatment of hepatitis.
About the Authors
A. V. Vatazin
M.F. Vladimirsky Moscow regional clinical research institute, Moscow
Russian Federation
Russian Federation
E. I. Prokopenko
M.F. Vladimirsky Moscow regional clinical research institute, Moscow
Russian Federation
Russian Federation
A. B. Zulkarnaev
M.F. Vladimirsky Moscow regional clinical research institute, Moscow
Russian Federation
Russian Federation
R. O. Kantaria
M.F. Vladimirsky Moscow regional clinical research institute, Moscow
Russian Federation
Russian Federation
D. V. Artemov
M.F. Vladimirsky Moscow regional clinical research institute, Moscow
Russian Federation
Russian Federation
References
1. Прокопенко Е.И., Ватазин А.В., Щербакова Е.О. Инфекционные осложнения после трансплантации почки Руководство по инфекционным болезням. М.: ИПО «УНикитскихворот», 2010. 296 с.
2. Ahn H.J., Kim M.S., Kim Y.S. et al. Clinical outcome of renal transplantation in patients with positivepre-transplanthepatitis B surface antigen // J. Med. Virol. 2007. Vol. 79. № 11. P. 1655–1663.
3. Baid-Agrawal S.,Pascual M., Moradpour D. et al. Hepatitis C virus infection in haemodialysis and kidney transplant patients // Rev. Med. Virol. 2008. Vol. 18. № 2. P. 97–115.
4. Braks R.E., Ganne-Carrie N., Fontaine H. et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin // World J. Gastroenterol. 2007. Vol. 13. № 42. P. 5648–5653.
5. Cardoso A.C., Moucari R., Figueiredo-Mendes C. et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis // J Hepatol. 2010. Vol. 52. № 5. P. 652–657.
6. Di Martino V., Crouzet, J., Hillon P. et al. Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis // J. Viral. Hepat. 2011. Vol. 18. № 7. P. 493–505.
7. Domínguez-Gil B., Morales J.M. Transplantation in the patient with hepatitis C // Transpl Int. 2009. Vol. 22. № 12. P. 1117–1131.
8. Einollahi B., Alavian S.M. Hepatitis C virus infection and kidney transplantation: a review for clinicians // Iran J Kidney Dis. 2010. Vol. 4. № 1. P. 1–8.
9. El-Farrash M.A., Aly H.H., Watashi K. et al. In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporine // Microbiol. Immunol. 2007. Vol. 51. № 1. P. 127–133.
10. Fabrizi F., Bromberg J., Elli A. et al. Review article: hepatitis C virus and calcineurin inhibition after renal transplantation // Aliment. Pharmacol. Ther. 2005. Vol. 22. № 8. Р. 657–666.
11. Fabrizi F., Bunnapradist S., Martin P. Treatment of hepatitis C in potential kidney and heart transplant patients // Clin. Liver Dis. 2005. Vol. 9. № 3. P. 487–503.
12. Fabrizi F., Lunghi G., Ganeshan S.V. et al. Hepatitis C virus infection and the dialysis patient // Semin Dial. 2007. Vol. 20. № 5. P. 416–422.
13. Fabrizi F., Poordad F.F., Martin P. Hepatitis C infection and the patient with end-stage renal disease // Hepatology. 2002. Vol. 36. № 1. P. 3–10.
14. Fischer G., Gallay P., Hopkins S. et al. Cyclophilin inhibitors for the treatment of HCV infection // Curr. Opin. Investig. Drugs. 2010. Vol. 11. № 8. P. 911–918.
15. Fujiwara K., Kaneko S., Kakumu S. et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load // Hepatol. Res. 2007. Vol. 37. № 9. P. 701–710.
16. Gordon C.E., Uhlig K.,Lau J. et al. Interferon for hepatitis C virus in hemodialysis an individual patient meta-analysis of factors associated with sustained virological response // Clin. J. Am. Soc. Nephrol. 2009. Vol. 4. № 9. P. 1449–1458.
17. Gordon C.E., Uhlig K.,Lau J. et al. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms // Am. J Kidney Dis. 2008. Vol. 51. № 2. P. 263–277.
18. Gwak G.Y., Huh W., Lee D.H. et al. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy // Transplant Proc. 2007. Vol. 39. № 10. P. 3121–3126.
19. Hanafusa N., Kondo Y., Suzuki M. et al. Double filtration plasmapheresis can decrease factor XIII Activity // Ther. Apher. Dial. 2007. Vol. 11. № 3. P. 165–170.
20. Hanafusa N., Satonaka H., Doi K. et al. Virus removal and eradication by modified double filtration plasmapheresis decreases factor XIII levels // Ther. Apher. Dial. 2010. Vol. 14. № 3. P. 287–291.
21. Henry S.D., Metselaar H.J., Lonsdale R.C. et al.Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha // Gastroenterology. 2006. Vol. 131. № 5. P. 1452–1462.
22. Hu T.H., Tsai M.C., Chien Y.S. et al. A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients. // AntivirTher. 2012. Vol. 17. № 4. P. 745–753.
23. Iacobellis A., Perri F., Valvano M.R. et al. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis // Clin. Gastroenterol. Hepatol. 2011. Vol. 9. № 3. P. 249–253.
24. Ishikawa T., Higuchi K., Kubota T. et al. Complete early virological response was highly achieved by double filtration plasmapheresis plus IFN-beta induction therapy for HCV-1b patients with relapse or no response after previous IFN therapy // Ther. Apher. Dial. 2011. Vol. 15. № 4. P. 400–405.
25. Jeon J.W., Shin H.P., Lee J.I. et al. Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B // Dig Dis Sci. 2012. Vol. 57. № 5. P. 1358–1365.
26. Kahraman A., Witzke O., Scherag A. et al. Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation // Clin. Nephrol. 2011. Vol. 75. № 1. P. 16–25.
27. Kalia H., Lopez P.M., Martin P. Treatment of HCV in patients with renal failure // Arch. Med. Res. 2007. Vol. 38. № 6. P. 628–633.
28. Kamar N., Ribes D., Izopet J., Rostaing L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant // Transplantation. 2006. Vol. 82. № 7. Р. 853–856.
29. Kamar N., Huart A., Tack I. Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients // Clin Nephrol. 2009. Vol. 71. № 1. P. 36–42.
30. Kaneko S., Sata M., Ide T. et al. Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C // Hepatol. Res. 2010. Vol. 40. № 11. P. 1072–1081.
31. Kes P., Basic-Jukic N. Hepatitis C in dialysed patients what is the current optimal treatment? // Kidney Blood Press Res. 2007. Vol. 30. № 3. P. 156–161.
32. Kim E., Ko H.H., Yoshida E.M. Treatment issues surrounding hepatitis C in renal transplantation: a review // Ann. Hepatol. 2011. Vol. 10. № 1. P. 5–14.
33. Kim S.R., Imoto S., Kudo M. et al. Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics // Intervirology. 2010. Vol. 53. № 1. P. 44–48.
34. Kondo Y., Ueno Y., Wakui Y. et al. Rapid reduction of hepatitis C virus-Core protein in the peripheral blood improve the immunological response in chronic hepatitis C patients // Hepatol Res. 2011. Vol. 41. № 12. P. 1153–1168.
35. Konishi I., Horiike N., Michitaka K. et al. Renal transplant recipient with chronic hepatitis C who obtained sustained viral response after interferon-beta therapy // Intern. Med. 2004. Vol. 43. № 10. P. 931–934.
36. Lampertico P., Viganò M., Facchetti F. et al. Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B // Nephrol Dial Transplant. 2011. Vol. 26. № 6. P. 2037–2041.
37. Levent F. Double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C // Hepatol. Res. 2011. Vol. 41. № 2. P. 197.
38. Li M.W., Hou W., Wo J.E. et al. Characterof HBV (hepatitis Bvirus) polymer asegenert M204V/I and rtL180M mutation in patients with lamivud in eresistance // J. Zhejiang Univ. Sci. B. 2005. Vol. 6. № 7. P. 664–667.
39. Manga Sahin G., Sahin S., Kantarci G., Ergin H. Impact of hepatitis C virus infection on patient and graft survival in kidney transplantation // Transplant Proc. 2006. Vol. 38. № 2. P. 499–501.
40. Martin P., Fabrizi F. Hepatitis C virus and kidney disease // J Hepatol. 2008. Vol. 49. № 4. P. 613–624.
41. Matos C.A., Perez R.M., Lemos L.B. et al. Factors associated with the intensity of liver fibrosis in renal transplant patients with hepatitis B virus infection // Eur. J Gastroenterol. Hepatol. 2007. Vol. 19. № 8. P. 653–657.
42. Morales J.M., Marcén R., Andres A. et al. Renal transplantation in patients with hepatitis C virus antibody. A long national experience // NDT Plus. 2010. Vol. 3. Suppl. 2. P. 41–46.
43. Mousa D.H., Abdalla A.H., Al-Shoail G. et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C // Transplant Proc. 2004. Vol. 36. № 6. P. 1831–1834.
44. Namba T., Shiba R., Yamamoto T. et al. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy // Clin. Exp. Nephrol. 2010. Vol. 14. № 4. P. 372–376.
45. Nanmoku K., Imaizumi R., Tojimbara T. et al. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy // Transplant. Proc. 2008. Vol. 40. № 7. Р. 2382–2385.
46. Ohara T., Oteki T., Suzuki T. et al. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination // Hepatogastroenterology. 2011. Vol. 58. № 105. P. 133–136.
47. Park K.S., Yang W.S., Han D.J. et al. Long-term impact of prophylactic antiviral treatment in Hepatitis B surface antigenpositive renal allograft recipients // ClinNephrol. 2012. Vol. 78. № 4. P. 303–311.
48. Perrillo R.P., Hann H.W., Schiff E. et al. Extended treatment withlamivudineand adefovirdipivoxil in chronichepatitisB patients withlamivudineresistance // Hepatol. Int. 2011. Vol. 5. № 2. P. 654–663.
49. Rapti I.N., Hadziyannis S.J. Treatment of special populations with chronic hepatitis B infection // Expert Rev Gastroenterol Hepatol. 2011. Vol. 5. № 3. P. 323–339.
50. Sharma R.K., Bansal S.B., Gupta A. et al. Chronic hepatitis C virus infection in renal transplant: treatment and outcome // Clin. Transplant. 2006. Vol. 20. № 6. P. 677–683.
51. Takada Y., Ito T., Ueda Y. et al. Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation // Liver Transpl. 2008. Vol. 14. № 7. P. 1044–1047.
52. Tang I.Y., Walzer N., Aggarwal N. et al. Management of the kidney transplant patient with chronic hepatitis C infection // Int. J. Nephrol. 2011. Vol. 2011. P. 245823.
53. Taniguchi M., Furukawa H., Shimamura T. et al. Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients withhepatitis C // Transplantation. 2006. Vol. 81. № 12. P. 1747–1749.
54. Torre F., Giannini E.G., Basso M. et al. Initial high dose oflamivudinedelays the appearance of viralresistancein chronichepatitisB patients // J. Gastrointestin. Liver. Dis. 2011. Vol. 20. № 1. P. 47–50.
55. Trapero-Marugán M., Mendoza J., Chaparro M. et al. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin // World J Gastroenterol. 2011. Vol. 17. № 4. P. 493–498.
56. Tsai M.C., Chen Y.T., Chien Y.S. et al. Hepatitis B virus infection and renal transplantation // World J Gastroenterol. 2010. Vol. 16. № 31. P. 3878–3887.
57. Tullis R.H., Duffin R.P., Ichim T.E. et al. Modeling hepatitis C virus therapies combining drugs and lectin affinity plasmapheresis // Blood Purif. 2010. Vol. 29. № 2. P. 210–215.
58. Vallet-Pichard A., Fontaine H., Mallet V., Pol S. VIRAL hepatitis in solid organ transplantation other than liver // J Hepatol. 2011. Vol. 55. № 2. P. 474–482.
59. Wong J.B., Davis G.L., McHutchison J.G. et al. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C // Am J Gastroenterol. 2003. Vol. 98. № 11. P. 2354–2362.
60. Yamashita T., Arai K., Sakai A. et al. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronichepatitis C: A preliminary study // Hepatol. Res. 2006. Vol. 36. № 3. P. 167–175.
61. Yap D.Y., Tang C.S., Yung S. et al. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments // Transplantation. 2010. Vol. 90. № 3. P. 325–330.
Review
For citations:
Vatazin A.V., Prokopenko E.I., Zulkarnaev A.B., Kantaria R.O., Artemov D.V. Treatment of viral hepatitis in recipients of renal allograft (Review). Nephrology and Dialysis. 2013;15(1):54-58.
Views:
25
Email this article 